TopicalDosed ingredientTherapeutic flag Cosmetic cross-reference

Azelaic Acid

CAS 123-99-9

Azelaic Acid (CAS 123-99-9) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 3,124 adverse event associations.

SOURCE NLM DailyMed
Label records
2
SOURCE EMBL-EBI ChEMBL
Bioactivity
4
SOURCE DrugCentral
Adverse signals
3,124
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Azelaic Acid
CAS Number
123-99-9
UNII
F2VW3D43YT
InChIKey
BDJRBEYXGGNYIS-UHFFFAOYSA-N
ChEMBL ID
CHEMBL1238
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
AzelexFinacea
dosed ingredientnatural producttherapeutic flagtopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL1238 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 2 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
AOAO Acne Buster Salicylic Acid Drying Serum AZELAIC ACID
F2VW3D43YT
 AZELAIC ACID 20260506
PEGO Acne Buster Salicylic Acid Drying Serum AZELAIC ACID
F2VW3D43YT
 AZELAIC ACID 20260505
SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

TargetActivity ValueAssaysOrganism
- AC50 13804.878787878788 nM 66 -
- Potency 19793.391304347828 nM 21 -
- IC50 19976.309999999998 nM 1 -
3-oxo-5-alpha-steroid 4-dehydrogenase 2
Enzyme
 - - - Homo sapiens
SOURCE DrugCentral 19 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Blepharospasm 77 382.651 10005159
Taste disorder 79 314.58 10082490
Epilepsy 77 240.351 10015037
Migraine 85 198.362 10027599
Gastrooesophageal reflux disease 81 176.888 10017885
Memory impairment 81 171.717 10027175
Paraesthesia 89 161.642 10033775
Hypoaesthesia 80 134.246 10020937
Abdominal pain upper 84 128.267 10000087
Drug intolerance 78 90.997 10061822
Pain 107 73.849 10033371
Vomiting 90 61.611 10047700
Product use in unapproved indication 57 59.84 10076476
Burning sensation 26 44.206 10006784
Rosacea 12 39.9 10039218
Application site erythema 12 37.94 10003041
Application site pain 11 35.156 10003051
Drug ineffective 103 33.837 10013709
Transposition of the great vessels 7 32.413 10044443

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
AZELAIC ACID 18602 SU MTHSPL
Azelaic Acid 18602 SU MTHSPL
azelaic acid 18602 PIN RXNORM
Azelex 215499 BN RXNORM
Finacea 352645 BN RXNORM
SOURCE SIDER 47 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side EffectDrug Name MedDRA TypeConcept ID
Acne azelaic LLT C0702166
Acne azelaic PT C0702166
Application site reaction azelaic LLT C0151505
Application site reaction azelaic PT C0151505
Asthma azelaic LLT C0004096
Asthma azelaic PT C0004096
Dermatitis azelaic LLT C0011603
Dermatitis azelaic PT C0011603
Dermatitis azelaic PT C0011603
Dermatitis contact azelaic LLT C0011616
Dermatitis contact azelaic PT C0011616
Dry skin azelaic LLT C0151908
Dry skin azelaic PT C0151908
Erythema azelaic LLT C0041834
Erythema azelaic PT C0041834
Erythema azelaic PT C0041834
Herpes labialis azelaic LLT C0019345
Hypersensitivity azelaic LLT C0020517
Hypersensitivity azelaic PT C0020517
Hypertrichosis azelaic LLT C0020555
Hypertrichosis azelaic PT C0020555
Iridocyclitis azelaic LLT C0022073
Iridocyclitis azelaic PT C0022073
Keratosis pilaris azelaic LLT C0263383
Keratosis pilaris azelaic PT C0263383
Leukoderma azelaic LLT C0162835
Leukoderma azelaic PT C0162835
Localized exfoliation azelaic LLT C0520893
Oedema azelaic LLT C0013604
Oedema azelaic PT C0013604
Oral herpes azelaic PT C0341012
Pain azelaic PT C0030193
Paraesthesia azelaic PT C0030554
Photosensitivity reaction azelaic PT C0162830
Phototoxicity azelaic LLT C1527358
Pruritus azelaic LLT C0033774
Pruritus azelaic PT C0033774
Rash azelaic LLT C0015230
Rash azelaic PT C0015230
Redness azelaic LLT C0332575
Skin exfoliation azelaic PT C0237849
Stinging azelaic LLT C0677500
Tingling sensation azelaic LLT C2242996
Vitiligo azelaic LLT C0042900
Vitiligo azelaic PT C0042900
Xerosis azelaic LLT C0259817
Xerosis azelaic PT C0259817
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Azelaic Acid used for in pharmaceutical contexts?

Azelaic Acid (CAS 123-99-9) appears in DailyMed active-ingredient label rows, including AOAO Acne Buster Salicylic Acid Drying Serum, PEGO Acne Buster Salicylic Acid Drying Serum.

What are the known adverse events for Azelaic Acid?

Azelaic Acid has 3,124 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blepharospasm, Taste disorder, Epilepsy, Migraine, Gastrooesophageal reflux disease. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Azelaic Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Azelaic Acid with EU status "permitted".

What clinical phase is Azelaic Acid in?

Azelaic Acid is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Azelaic Acid?

Azelaic Acid has 4 bioactivity rows in this page query. Rendered target entries include 3-oxo-5-alpha-steroid 4-dehydrogenase 2.